secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125361
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports Q3 net loss $76.8M; submits NDA for paltusotine; raises $575M
-------------------------------------------------------------------------------

- Net loss of $76.8M in Q3 2024 vs $57.5M in Q3 2023; revenue $0 vs $0.3M from SKK licensing.
- NDA submitted for paltusotine (oral somatostatin agonist) for acromegaly; FDA decision expected Dec 2024.
- Upsized public offering raised $575M gross; pro-forma cash ~$1.4B, funding operations into 2029.
- Four candidates in IND-enabling studies; first NDC platform candidate data at NANETS Nov 2024; TSH antagonist IND expected 2025.
- R&D expenses $61.9M (+41% YoY); G&A $25.9M (+67% YoY), driven by pipeline expansion and launch prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024125361/0000950170-24-125361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024125361/crnx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer